QUANTRX BIOMEDICAL CORPORATION: 10-K filed 2022-04-15

Name: QUANTRX BIOMEDICAL CORPORATION: 10-K filed 2022-04-15
Creator: QUANTRX BIOMEDICAL CORPORATION
License: https://creativecommons.org/licenses/by/4.0/

What QUANTRX BIOMEDICAL CORPORATION reported in its annual report filed 2022-04-15 (fiscal FY 2021): 19 published measures, 38 facts as tagged in accession 0001493152-22-010071.

This filing

Form: 10-K (annual report)
Filed: 2022-04-15
Fiscal period: fiscal FY 2021
Accession: 0001493152-22-010071 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All QUANTRX BIOMEDICAL CORPORATION filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2021-12-31	5,950	USD
At 2020-12-31	55,428	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2021-12-31	2,647,047	USD
At 2020-12-31	2,436,483	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2021-12-31	-2,641,097	USD
At 2020-12-31	-2,381,055	USD
At 2019-12-31	-2,128,321	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2021-12-31	5,950	USD
At 2020-12-31	55,428	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	-260,042	USD	365
2020-01-01 to 2020-12-31	-252,734	USD	366

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	-49,478	USD	365
2020-01-01 to 2020-12-31	-74,923	USD	366

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2021-12-31	-52,375,028	USD
At 2020-12-31	-52,114,986	USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	-43,383	USD	365
2020-01-01 to 2020-12-31	-60,624	USD	366

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2021-12-31	5,950	USD
At 2020-12-31	55,428	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	216,659	USD	365
2020-01-01 to 2020-12-31	216,720	USD	366

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2021-12-31	10,219	USD
At 2020-12-31	16,312	USD

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	12,333	USD	365
2020-01-01 to 2020-12-31	12,726	USD	366

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2021-12-31	78,696,461	shares
At 2020-12-31	78,696,461	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2021-12-31	48,876,398	USD
At 2020-12-31	48,876,398	USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

Period	Value	Unit	Days
At 2021-12-31	1,489,694	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	-260,042	USD	365
2020-01-01 to 2020-12-31	-252,734	USD	366

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	0	USD	365
2020-01-01 to 2020-12-31	0	USD	366

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	-216,659	USD	365
2020-01-01 to 2020-12-31	-192,110	USD	366

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	-6,093	USD	365
2020-01-01 to 2020-12-31	-21,300	USD	366

Inspect the source

Entity: QUANTRX BIOMEDICAL CORPORATION / CIK 0000820608
Captured: 2026-09-22 19:31 UTC
SEC response SHA-256: 9ed677f1f65a020d7443764a5b8258c716645c1ae82e75ef1907f7558ecaa289

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000820608.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))